Abnormal electrophysiological phenotypes and sleep deficits in a mouse model of Angelman Syndrome.
N A Copping, J L Silverman
PMID 33549123WHAT IT FOUND
Loss of maternal Ube3a in Angelman syndrome mice produced seizure-like responses after a seizure-provoking drug, more baseline EEG spiking and delta activity, less REM-like sleep, and fewer sleep spindles.
This describes a mouse phenotype, not a tested therapy.
Key findings
01Mice with maternal Ube3a deletion had shorter latency to first jerk and to generalized clonic-tonic seizure after pentylenetetrazole than wild-type littermates.
02During baseline EEG recordings, mice with maternal Ube3a deletion showed more epileptiform spiking and higher delta power than wild-type littermates.
03Mice with maternal Ube3a deletion had less time in paradoxical sleep, longer latency to paradoxical sleep, lower total sleep time, and fewer sleep spindles than wild-type littermates.
STILL TO COME
How it was doneWhat they found
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The study used mice, not people with Angelman syndrome, and it did not test any therapy. The seizure phenotype was provoked by pentylenetetrazole, not observed without the convulsant, and the background strain is relatively resistant to seizures. The EEG cohorts were small, and spiking analyses could not be combined across cohorts because recording times differed. The study did not examine brain anatomy or link spindle changes to cognitive behaviour. It used one exon 2 deletion mouse model, so findings may not apply to other Angelman syndrome genetic forms.
Declared interests
Funding came from the National Institute of Neurological Disorders and Stroke, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the Foundation for Angelman Syndrome Therapeutics. The article does not state author conflicts of interest.
The easy way to misread this
Do not read these mouse EEG and sleep findings as evidence that a therapy works for people with Angelman syndrome. The study tested mice, not patients, and did not evaluate treatment.